Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study von Yung, W.K. Alfred, Vredenburgh, James J., Cloughesy, Timothy F., Nghiemphu, Phioanh, Klencke, Barbara, Gilbert, Mark R., Reardon, David A., Prados, Michael D.

Volltext

Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials von Van Heertum, Ronald L, Scarimbolo, Robert, Wolodzko, John G, Klencke, Barbara, Messmann, Richard, Tunc, Feza, Sokol, Levi, Agarwal, Rajan, Strafaci, James A, O'Neal, Michael

Volltext

Azacitidine Induces Demethylation of the Epstein-Barr Virus Genome in Tumors von CHAN, Anthony T. C, QIAN TAO, ROBERTSON, Keith D, FLINN, Ian W, MANN, Risa B, KLENCKE, Barbara, WING HONG KWAN, LEUNG, Thomas Wai-Tong, JOHNSON, Philip J, AMBINDER, Richard F

Volltext

Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: A Phase I study of ZYC101 von KLENCKE, Barbara, MATIJEVIC, Mark, JAY, Naomi, DA COSTA, Maria, PALEFSKY, Joel M, URBAN, Robert G, LATHEY, Janet L, HEDLEY, Mary Lynne, BERRY, Michael, THATCHER, Joe, WEINBERG, Vivian, WILSON, Jennifer, DARRAGH, Teresa

Volltext

5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and ph... von Burris, H, Vukelja, S, Krop, I, Modi, S, Klencke, B, Girish, S, Sliwkowski, M.X, Dresser, M, Phillips, G.L, Rugo, H

Volltext

Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma von Benson III, A. B., Mitchell, E., Abramson, N., Klencke, B., Ritch, P., Burnham, J. P., McGuirt, C., Bonny, T., Levin, J., Hohneker, J.

Volltext

The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer von Hoffman, Rex, Welton, Mark L, Klencke, Barbara, Weinberg, Vivian, Krieg, Richard

Volltext

SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as first-line treatment for HER2-negative m... von Mayer, E, Kozloff, M, Qamar, R, Klencke, B, Balkissoon, J, Parmar, H, Samant, M, Burstein, HJ

Volltext

Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1) von Krop, I. E., Burris, H. A., Rugo, H., O'Shaughnessy, J., Vogel, C. L., Amler, L., Strauss, A., Wong, E. K., Klencke, B., Pippen, J.

Volltext

A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results von Vogel, C. L., Burris, H. A., Limentani, S., Borson, R., O'Shaughnessy, J., Vukelja, S., Agresta, S., Klencke, B., Birkner, M., Rugo, H.

Volltext

The restricted cellular host range of human herpesvirus 8 von BLACKBOURN, D. J, LENNETTE, E, HERNDIER, B, LEVY, J. A, KLENCKE, B, MOSES, A, CHANDRAN, B, WEINSTEIN, M, GLOGAU, R. G, WITTE, M. H, WAY, D. L, KUTZKEY, T

Volltext

A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer von Vukelja, S, Rugo, H, Vogel, C, Borson, R, Tan-Chiu, E, Birkner, M, Holden, SN, Klencke, B, O'Shaughnessy, J, Burris, HA

Volltext

Clinical pharmacokinetics of erlotinib (E) in glioblastoma multiforme (GBM) patients and its implication for dosing von Lu, J., Eppler, S., Ling, J., Prados, M., Klencke, B., Lum, B.

Volltext

P-492 A multicenter, open-label, phase Ilia trial of erlotinib in patients with advanced non-small cell lung cancer von Hainsworth, J., Spigel, D., O'Neill, V., Klencke, B.

Volltext

Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC) von Klencke, B. J., Bhattacharya, S., Samant, M. K., Gralow, J. R., Dickler, M. N., Cobleigh, M. A., Perez, E. A., Shenkier, T. N., Davidson, N. E., Miller, K. D.

Volltext

Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome von Cloughesy, T., Yung, A., Vrendenberg, J., Aldape, K., Eberhard, D., Prados, M., Vandenberg, S., Klencke, B., Mischel, P.

Volltext

Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial von Yung, A., Vredenburgh, J., Cloughesy, T., Klencke, B. J., Mischel, P. S., Bigner, D. D., Aldape, K., Vanderburg, S., Prados, M.

Volltext

Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial von Yung, A., Vredenburgh, J., Cloughesy, T., Klencke, B. J., Mischel, P. S., Bigner, D. D., Aldape, K., Vanderburg, S., Prados, M.

Volltext

Advances and future challenges in non-Hodgkinʼs lymphoma von Klencke, Barbara, Kaplan, Lawrence

Volltext

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer von Jones, R, Plummer, R, Moreno, V, Carter, L, Roda, D, Garralda, E, Kristeleit, R, Sarker, D, Arkenau, T, Roxburgh, P, Walter, HS, Blagden, S, Anthoney, A, Klencke, BJ, Kowalski, MM, Banerji, U

Volltext bestellen